Recent developments in Thermo Fisher Scientific Inc.'s stock ($TMO) indicate a complex mix of investments and divestments from various entities. Perpetual Ltd and Canoe Financial LP increased their holdings while Rep. Kelly Morrison and Burns J W & Co. Inc. decreased theirs. Other significant transactions included acquisitions by IFM Investors Pty Ltd, Triangle Securities Wealth Management, and Legacy Financial Strategies LLC. There've been positive movements following the company's announcement of a CFO succession and Barclays' upgrade. Solvency sold its purification & filtration business to Thermo Fisher Scientific, bolstering the company's offerings. Q2's performance, however, saw a downturn, attributed to factors undisclosed. Barclays upgraded its position to 'Overweight', and the launch of the Olink® Target 48 Neurodegeneration Panel has expanded the company's neurodegeneration research capabilities. Favourable financial reports and an increased outlook following strong results have also energised the stock. Finally, a strategic partnership with Sanofi was announced, strengthening its market standing.
Thermo Fisher Scientific TMO News Analytics from Thu, 08 May 2025 07:00:00 GMT to Sat, 20 Sep 2025 12:04:13 GMT - Rating 6 - Innovation 7 - Information 8 - Rumor -2
